Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Female representation — Senior Director level by Year
Female representation — Senior Director level (%) (%)
Pfizer Female representation — Senior Director level: 52.7% in FY2025, up 1.3 pts from a year earlier.
Latest, FY2025
52.7%
Period ended Dec 31, 2025
Change on a year earlier
+1.3 pts
51.4% in FY2024
History
3 years
Since FY2023
Sources
1
Pfizer Official Report — Pfizer 2025 Impact Report 02JUN2026
Where the FY2025 figure comes from
“Female 45.1% 52.7% 55.6% 54.9% 50.6%”
Source: Pfizer Official Report — Pfizer 2025 Impact Report 02JUN2026 ↗
Reported in Pfizer Annual Impact / ESG Report.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Female representation — Senior Director level (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.7% | +1.3 pts | Pfizer Official Report — Pfizer 2025 Impact Report 02JUN2026 ↗ |
| FY2024 | Dec 31, 2024 | 51.4% | +2.2 pts | Pfizer Official Report — Pfizer 2025 Impact Report 02JUN2026 ↗ |
| FY2023 | Dec 31, 2023 | 49.2% | – | Pfizer Official Report — Pfizer 2025 Impact Report 02JUN2026 ↗ |
Cite this data
StockData. (2026). Pfizer Female representation — Senior Director level (%), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/esg-fem-srdir
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.